The new pacemaker reduces complications that have existed over the last 50 years associated with lead placement and performance and the pulse generator situated under the skin that have occurred with conventional pacemaker systems.
In the first trial of the leadless pacemaker, doctors implanted one in eight patients (average 82 years old, 75 per cent men) with no complications in an average 41 minutes.
Researchers measured the device's performance at implant, after the patient was discharged and during three-, six- and twelve-month follow-up sessions.
The research was presented at the American Heart Association's Scientific Sessions 2014.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
